Subjects should not be vaccinated with live attenuated vaccines within one month prior to starting tremelimumab treatment
Vaccinated with live, attenuated vaccines within  weeks of first dose of study drug
Vaccinated with live, attenuated vaccines within  weeks of first dose of study drug
Patients should not be vaccinated with live attenuated vaccines within  month of starting tremelimumab and durvalumab treatment; subjects, if enrolled, should not receive live vaccine during the study and  days after the last dose of both drugs
Vaccinated with live, attenuated vaccines within  weeks of first dose of avelumab
Vaccinated with live, attenuated vaccines within  weeks of enrollment
Vaccinated with live, attenuated vaccine within  weeks or as recommended by the product manufacturer prior to the first dose, during treatment, or within  days of the last dose of JNJ-
Vaccinated with live, attenuated vaccines within  weeks of enrollment
Vaccinated with live, attenuated vaccines within  weeks of first dose of study drug.
Patients should not be vaccinated with live attenuated vaccines within  month of starting pembrolizumab treatment
Vaccinated with live, attenuated vaccine(s) within  days prior to first dose of study drug
Vaccinated with live, attenuated vaccine within  weeks of first dose of study drug
Vaccinated with live, attenuated vaccines within  weeks of enrollment
Vaccinated with live, attenuated vaccines within  weeks of first dose of study drug
Vaccinated with live, attenuated vaccines within  weeks of first dose of study drug
Vaccinated with live, attenuated vaccines within  weeks of enrollment
Vaccinated with live, attenuated vaccines within  weeks of first dose of study drug
Vaccinated with live, attenuated vaccines within  weeks of enrollment
Patients should not be vaccinated with live attenuated vaccines within  days of starting durvalumab or tremelimumab treatment
Vaccinated with live, attenuated vaccines within  weeks of first dose of study drug
Vaccinated with live, attenuated vaccines within  weeks of randomization
Vaccinated with live, attenuated vaccines within  weeks of study entry
Subjects should not be vaccinated with live attenuated vaccines within one month prior to starting tremelimumab treatment
Vaccinated with live, attenuated vaccines within  weeks of initiation of therapy
Vaccinated with live, attenuated vaccines within  weeks of first dose of study drug
Vaccinated with live, attenuated vaccines within  weeks of first dose of study drug
Vaccinated with live, attenuated vaccines within  weeks of first dose of study drug
Patient has been vaccinated with live attenuated vaccines within  weeks before study vaccination
Vaccinated with live, attenuated vaccines within  weeks of first dose of study drug
Vaccinated with live, attenuated vaccines within  weeks of study entry
Vaccinated with any of the vaccines planned for administration in the trial within  weeks of starting treatment on the study
Vaccinated with live, attenuated vaccines within  weeks of first dose of study drug
Patients should not be vaccinated with live attenuated vaccines within  month of starting tremelimumab and/or durvalumab (MEDI) treatment
Vaccinated with live, attenuated vaccines within  weeks of the first dose of study drug
Vaccinated with live attenuated vaccines =<  weeks from starting study drugs
Subjects should not be vaccinated with live attenuated vaccines within one month prior to starting tremelimumab treatment
Vaccinated with live, attenuated vaccines within  weeks of study entry
Subjects that have been vaccinated with live, attenuated vaccines within  weeks of the first dose of study drug are not eligible
Patient must not be vaccinated with live, attenuated vaccines within  weeks of first dose of study drug
Vaccinated with live attenuated vaccines within  weeks of first dose of study drug
Vaccinated with live, attenuated vaccines within  weeks of first dose of study drug
Patients should not be vaccinated with live attenuated vaccines within  month of starting tremelimumab treatment
Vaccinated with live, attenuated vaccines within  weeks of first dose of study drug
Vaccinated with live, attenuated vaccines within  weeks of initiation of therapy
Vaccinated with live, attenuated vaccines within  weeks of enrollment
Vaccinated with live, attenuated vaccines within  weeks of first dose of study drug.
Vaccinated with live, attenuated vaccines with  weeks of first does of study drug
Vaccinated with live, attenuated vaccines =<  weeks prior to registration
Vaccinated with live, attenuated vaccines within  weeks of treatment
Vaccinated with live, attenuated vaccines within  weeks of starting ibrutinib
Vaccinated with live, attenuated vaccines within  weeks of first dose of study drug
Vaccinated with live, attenuated vaccines within  weeks of first dose of study drug
EXCLUSION CRITERIA (PRIOR TO IBRUTINIB ADMINISTRATION): Vaccinated with live, attenuated vaccines within  weeks of first dose of study drug
Vaccinated with live, attenuated vaccines within four weeks of the first dose of study drug
